ExchangeCoverageMedium impact
Exchange formulary update – January 1, 2020
Blue Cross Blue Shield of Rhode Island·RI · Endocrinology, Pediatrics·Physician / Facility
Effective date
Jan 1, 2020
We identified it
Jun 20, 2026
Summary
Exchange formulary update effective January 1, 2020 changes the preferred growth hormone to Norditropin. All existing patients using alternative growth hormone products must transition to Norditropin with support from specialty pharmacy vendors and PCMH pharmacists.
Action Required
By January 1, 2020: Billing team must coordinate with specialty pharmacy vendor and PCMH pharmacists to transition all patients currently using alternative growth hormone products to Norditropin. Update billing records to reflect formulary preference for Norditropin over other growth hormone products for exchange plan members. Verify specialty pharmacy network access for continued coverage.